skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
español
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page


<< Back

Funding

Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01)

Description
Grant Amount: Unspecified.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the high-risk research needed to develop new and innovative sustained release antiviral strategies for treatment of HIV disease or the prevention of HIV transmission and acquisition. Adherence to dosing regimens is a shared critical issue for both HIV treatment and prevention. It has been hypothesized that development of approaches eliminating or reducing the impact of individual adherence could increase the efficacy of treatment strategies and provide for prevention of HIV transmission. Although initial development of sustained release methods for prevention and treatment have begun, the effort is limited in scope and is not taking full advantage of available antivirals and the range of new and novel formulation approaches to achieve sustained release of drugs.

Clinical experience for both the HIV treatment and prevention fields has established that adherence is a significant factor in the success of the HIV treatment regime and/or prevention strategies. Effective treatment of HIV-infected individuals requires strict adherence to a multi-component regimen of antiretroviral agents that currently must be taken at least daily for the remainder of a patient’s life. Non-adherence can lead to emergence of drug-resistance and loss of therapeutic effectiveness. Effective prevention requires that the inhibitor be present at the right time, place and concentration to stop HIV transmission and acquisition. Although many factors (social, behavioral and individual preference) can influence adherence, one that is addressable using drug discovery/development tools is the use of drug delivery systems to provide for a longer therapeutic exposure or window of protection, thus lowering the barrier to achievement of consistent use by the infected and/or uninfected individual. The goal of developing safe, effective and well-tolerated acceptable sustained release formulations/regimens is thus to improve adherence by significantly simplifying dosing requirements while maintaining consistent and effective drug levels in plasma and HIV target tissues (CNS/CSF, semen, lymph nodes, female reproductive tract, GALT, etc.).



Funding Organization
National Institute of Allergy and Infectious Diseases
Division of AIDS
Eunice Kennedy Shriver National Institute of Child Health and Human Development
US Department of Health and Human Services
Public Health Services
National Institutes of Health
National Institute of Mental Health
Fund Category
HIV/AIDS
Support Types
Research
Locations
International
National
Eligible Organizations
City Agencies
Colleges/Universities
Commercial Organizations
Community Based Organizations
County Agencies
Educational Organizations/Institutions
Federal Government Agencies
International Agencies
IRS 501 (c)(3) Organizations
Nonprofit Organizations
Religious Organizations
Schools
State Agencies
Tribal Organizations
Award Amount Notes
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Application budgets are not limited, but need to reflect the actual needs of the proposed project.

Application Due Date
1/7/2016
Project Start Date
7/1/2016
Application Contact
GrantsInfo
,
Phone: (301) 435-0714
Technical Contact
Steven R Turk
Division of AIDSNIAID

Phone: (301) 435-3771
Fund Duration
Up to 5 years.
Subjects
Antiviral Drugs
HIV/AIDS Prevention
Medical Treatments and Therapies
Research Programs
Audiences
Researchers
Application Process
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Web Site
http://grants.nih.gov/grants/guide/pa-files/PAR-13-349.html
Fund Number
PAR -13-349

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.

cdcnpin.org Fund Record #4749

<< Back

CDCNPIN.org

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources

hivtest.cdc.gov
m.hivtest.cdc.gov
findtbresources.org
STD Awareness Microsite
findstdtest.org
AIDS Gov Logo and Link CDC Logo and Link